DJIA 17,751.39 121.12 0.69%
NASDAQ 5,111.73 22.53 0.44%
S&P 500 2,108.57 15.32 0.73%
market minute promo

TAKEDA PHARM CO LTD S/ADR (NASDAQOTH: TKPYY)

24.81 0.14 (0.57%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

TKPYY $24.81 0.57%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $24.58
Previous Close $24.67
Daily Range $24.58 - $24.82
52-Week Range $20.36 - $27.52
Market Cap $39.2B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.6%)
Volume 6,681
Average Daily Volume 38,389
Current FY EPS $0.39

Sector

Industry

TAKEDA PHARM CO LTD S/ADR (TKPYY) Description

Website:

News & Commentary

Why Shares of Orexigen Therapeutics, Inc. Cratered Today

Orexigen Therapeutics is crashing today following more bad news for its diet pill Contrave. Here's what investors need to know right now.

Why It's Lights Out for Orexigen Therapeutics, Inc.

Orexigen Therapeutics shares tumble after the company announces the termination of a critical post-marketing approval study for Contrave.

5 Largest Markets for Pharmaceuticals

The pharmaceutical market is headed for $1.3 trillion by 2016. Here's how globalization is radically changing the game for Big Pharma and Big Biotech players.

Why ImmunoGen Inc. Shares Tumbled Today

After reporting first-quarter financials Friday, ImmunoGen Inc.'s shares fell despite bullish analyst reports.

Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch

Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.

Forget About Ebola Stocks and Invest in This Instead

Instead of Ebola drugmakers, investors may be better served focusing on these healthcare trends.

Which Biotech Stock Should Pfizer, Inc. Buy?

Motley Fool contributors offer up three potential acquisition targets for Pfizer.

Newly Approved Weight Loss Method Works by Tricking Your Brain

What's the best way to lose weight? One company thinks it's simple: don't get hungry.

Why Seattle Genetics, Inc. Stock Dove 12% in December

Seattle Genetics' shares get hammered following impressive clinical data from its rivals at the American Society of Hematology's annual meeting. Find out whether this dip represents a buying opportunity or a red flag.

Buying These 3 Stocks Is Like Making a Bet in a Burning House

Aegerion Pharmaceuticals, MannKind Corp., and VIVUS, Inc. have all attracted short sellers in droves this year. With each company facing serious headwinds, should investors avoid these struggling biotechs?

See More TKPYY News...